Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 12, 2023
Distillery Therapeutics

A dual HDAC3 and HDAC8 degrader for breast cancer

BioCentury | Aug 14, 2023
Discovery & Translation

E3 ligase pathways for liver diseases, a trypanosome RPA1 inhibitor and more

New targets and compounds from BioCentury’s Distillery
BioCentury | Aug 11, 2023
Distillery Therapeutics

Inhibiting HDAC1 for pain and opioid withdrawal

BioCentury | Jul 12, 2019
Financial News

HitGen joins growing Shanghai IPO queue

BioCentury | May 17, 2019
Product Development

Pushing China to the forefront: When a first-in-China regulatory strategy makes sense

How patient prevalence and market access could encourage companies to launch their drugs first in China.
BioCentury | Nov 9, 2018
Tools & Techniques

HitGen’s DNA for small molecules

How HitGen is amplifying DNA-encoded library-based drug design
BioCentury | Aug 8, 2018
Distillery Therapeutics

Cancer

Items per page:
1 - 10 of 45